372 related articles for article (PubMed ID: 34065940)
1. Antibiotic Therapy of Plague: A Review.
Sebbane F; Lemaître N
Biomolecules; 2021 May; 11(5):. PubMed ID: 34065940
[TBL] [Abstract][Full Text] [Related]
2. Curative Treatment of Severe Gram-Negative Bacterial Infections by a New Class of Antibiotics Targeting LpxC.
Lemaître N; Liang X; Najeeb J; Lee CJ; Titecat M; Leteurtre E; Simonet M; Toone EJ; Zhou P; Sebbane F
mBio; 2017 Jul; 8(4):. PubMed ID: 28743813
[TBL] [Abstract][Full Text] [Related]
3. Cethromycin-mediated protection against the plague pathogen Yersinia pestis in a rat model of infection and comparison with levofloxacin.
Rosenzweig JA; Brackman SM; Kirtley ML; Sha J; Erova TE; Yeager LA; Peterson JW; Xu ZQ; Chopra AK
Antimicrob Agents Chemother; 2011 Nov; 55(11):5034-42. PubMed ID: 21859946
[TBL] [Abstract][Full Text] [Related]
4. Decrypting the multi-genome data for chimeric vaccine designing against the antibiotic resistant Yersinia pestis.
Sarfraz A; Qurrat-Ul-Ain Fatima S; Shehroz M; Ahmad I; Zaman A; Nishan U; Tayyab M; Sheheryar ; Moura AA; Ullah R; Ali EA; Shah M
Int Immunopharmacol; 2024 May; 132():111952. PubMed ID: 38555818
[TBL] [Abstract][Full Text] [Related]
5. Use of an in vitro pharmacodynamic model to derive a moxifloxacin regimen that optimizes kill of Yersinia pestis and prevents emergence of resistance.
Louie A; Heine HS; VanScoy B; Eichas A; Files K; Fikes S; Brown DL; Liu W; Kinzig-Schippers M; Sörgel F; Drusano GL
Antimicrob Agents Chemother; 2011 Feb; 55(2):822-30. PubMed ID: 21115791
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Human Plague: A Systematic Review of Published Aggregate Data on Antimicrobial Efficacy, 1939-2019.
Godfred-Cato S; Cooley KM; Fleck-Derderian S; Becksted HA; Russell Z; Meaney-Delman D; Mead PS; Nelson CA
Clin Infect Dis; 2020 May; 70(70 Suppl 1):S11-S19. PubMed ID: 32435800
[TBL] [Abstract][Full Text] [Related]
7. In vitro efficacy of antibiotics commonly used to treat human plague against intracellular Yersinia pestis.
Wendte JM; Ponnusamy D; Reiber D; Blair JL; Clinkenbeard KD
Antimicrob Agents Chemother; 2011 Aug; 55(8):3752-7. PubMed ID: 21628541
[TBL] [Abstract][Full Text] [Related]
8. [Yersinia pestis and plague - an update].
Stock I
Med Monatsschr Pharm; 2014 Dec; 37(12):441-8; quiz 449. PubMed ID: 25643450
[TBL] [Abstract][Full Text] [Related]
9. Postexposure Administration of a Yersinia pestis Live Vaccine for Potentiation of Second-Line Antibiotic Treatment Against Pneumonic Plague.
Zauberman A; Gur D; Levy Y; Aftalion M; Vagima Y; Tidhar A; Chitlaru T; Mamroud E
J Infect Dis; 2019 Aug; 220(7):1147-1151. PubMed ID: 31095689
[TBL] [Abstract][Full Text] [Related]
10. Treatment of plague: promising alternatives to antibiotics.
Anisimov AP; Amoako KK
J Med Microbiol; 2006 Nov; 55(Pt 11):1461-1475. PubMed ID: 17030904
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of protective potential of Yersinia pestis outer membrane protein antigens as possible candidates for a new-generation recombinant plague vaccine.
Erova TE; Rosenzweig JA; Sha J; Suarez G; Sierra JC; Kirtley ML; van Lier CJ; Telepnev MV; Motin VL; Chopra AK
Clin Vaccine Immunol; 2013 Feb; 20(2):227-38. PubMed ID: 23239803
[TBL] [Abstract][Full Text] [Related]
12. In vitro activities of 14 antibiotics against 100 human isolates of Yersinia pestis from a southern African plague focus.
Frean JA; Arntzen L; Capper T; Bryskier A; Klugman KP
Antimicrob Agents Chemother; 1996 Nov; 40(11):2646-7. PubMed ID: 8913481
[TBL] [Abstract][Full Text] [Related]
13. Braun lipoprotein (Lpp) contributes to virulence of yersiniae: potential role of Lpp in inducing bubonic and pneumonic plague.
Sha J; Agar SL; Baze WB; Olano JP; Fadl AA; Erova TE; Wang S; Foltz SM; Suarez G; Motin VL; Chauhan S; Klimpel GR; Peterson JW; Chopra AK
Infect Immun; 2008 Apr; 76(4):1390-409. PubMed ID: 18227160
[TBL] [Abstract][Full Text] [Related]
14. A Deadly Path: Bacterial Spread During Bubonic Plague.
Gonzalez RJ; Miller VL
Trends Microbiol; 2016 Apr; 24(4):239-241. PubMed ID: 26875618
[TBL] [Abstract][Full Text] [Related]
15. Yersinia pestis subverts the dermal neutrophil response in a mouse model of bubonic plague.
Shannon JG; Hasenkrug AM; Dorward DW; Nair V; Carmody AB; Hinnebusch BJ
mBio; 2013 Aug; 4(5):e00170-13. PubMed ID: 23982068
[TBL] [Abstract][Full Text] [Related]
16. Activation of Heme Oxygenase Expression by Cobalt Protoporphyrin Treatment Prevents Pneumonic Plague Caused by Inhalation of
Willix JL; Stockton JL; Olson RM; Anderson PE; Anderson DM
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015027
[TBL] [Abstract][Full Text] [Related]
17. Assessment of a fluoroquinolone, three beta-lactams, two aminoglycosides, and a cycline in treatment of murine Yersinia pestis infection.
Bonacorsi SP; Scavizzi MR; Guiyoule A; Amouroux JH; Carniel E
Antimicrob Agents Chemother; 1994 Mar; 38(3):481-6. PubMed ID: 8203841
[TBL] [Abstract][Full Text] [Related]
18. Plague vaccines and the molecular basis of immunity against Yersinia pestis.
Quenee LE; Schneewind O
Hum Vaccin; 2009 Dec; 5(12):817-23. PubMed ID: 19786842
[TBL] [Abstract][Full Text] [Related]
19. Yersinia pestis endowed with increased cytotoxicity is avirulent in a bubonic plague model and induces rapid protection against pneumonic plague.
Zauberman A; Tidhar A; Levy Y; Bar-Haim E; Halperin G; Flashner Y; Cohen S; Shafferman A; Mamroud E
PLoS One; 2009 Jun; 4(6):e5938. PubMed ID: 19529770
[TBL] [Abstract][Full Text] [Related]
20. Complete Protection against Pneumonic and Bubonic Plague after a Single Oral Vaccination.
Derbise A; Hanada Y; Khalifé M; Carniel E; Demeure CE
PLoS Negl Trop Dis; 2015; 9(10):e0004162. PubMed ID: 26473734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
